Title : Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.

Pub. Date : 2021 Jun 15

PMID : 33690902






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PSA50 responses to carboplatin-based chemotherapy were higher for BRCA1/2 (79%) than ATM (14%; P = .02) or CDK12 (38%; P = .08). Carboplatin BRCA1 DNA repair associated Homo sapiens